251 related articles for article (PubMed ID: 31933413)
1. Promoter aberrant methylation status of
Chen G; Fan X; Li Y; He L; Wang S; Dai Y; Bin C; Zhou D; Lin H
Epigenetics; 2020; 15(6-7):684-701. PubMed ID: 31933413
[TBL] [Abstract][Full Text] [Related]
2. Clinical significance of aberrant cyclin-dependent kinase-like 2 methylation in hepatocellular carcinoma.
Zhou Y; Qiu XP; Li ZH; Zhang S; Rong Y; Yang GH; Fang-Zheng
Gene; 2019 Jan; 683():35-40. PubMed ID: 30292871
[TBL] [Abstract][Full Text] [Related]
3. Epigenomic profiling of DNA methylation for hepatocellular carcinoma diagnosis and prognosis prediction.
Zhang C; Ge S; Wang J; Jing X; Li H; Mei S; Zhang J; Liang K; Xu H; Zhang X; Zhang C
J Gastroenterol Hepatol; 2019 Oct; 34(10):1869-1877. PubMed ID: 31038805
[TBL] [Abstract][Full Text] [Related]
4. The association between methylation patterns of DNAH17 and clinicopathological factors in hepatocellular carcinoma.
Fan X; Guo H; Dai B; He L; Zhou D; Lin H
Cancer Med; 2019 Jan; 8(1):337-350. PubMed ID: 30575322
[TBL] [Abstract][Full Text] [Related]
5. Aberrant methylation status of SPG20 promoter in hepatocellular carcinoma: A potential tumor metastasis biomarker.
He L; Fan X; Li Y; Cui B; Shi Z; Zhou D; Lin H
Cancer Genet; 2019 Apr; 233-234():48-55. PubMed ID: 31109594
[TBL] [Abstract][Full Text] [Related]
6. Methylation of IRAK3 is a novel prognostic marker in hepatocellular carcinoma.
Kuo CC; Shih YL; Su HY; Yan MD; Hsieh CB; Liu CY; Huang WT; Yu MH; Lin YW
World J Gastroenterol; 2015 Apr; 21(13):3960-9. PubMed ID: 25852282
[TBL] [Abstract][Full Text] [Related]
7. CHD5 a tumour suppressor is epigenetically silenced in hepatocellular carcinoma.
Zhao R; Wang N; Huang H; Ma W; Yan Q
Liver Int; 2014 Jul; 34(6):e151-60. PubMed ID: 24529164
[TBL] [Abstract][Full Text] [Related]
8. Aberrant TIG1 methylation associated with its decreased expression and clinicopathological significance in hepatocellular carcinoma.
Chen XH; Wu WG; Ding J
Tumour Biol; 2014 Feb; 35(2):967-71. PubMed ID: 24006221
[TBL] [Abstract][Full Text] [Related]
9. Promoter hypermethylation of DNA damage response genes in hepatocellular carcinoma.
Li Z; Zhang H; Yang J; Hao T; Li S
Cell Biol Int; 2012 May; 36(5):427-32. PubMed ID: 21864295
[TBL] [Abstract][Full Text] [Related]
10. Promoter hypomethylation up-regulates CD147 expression through increasing Sp1 binding and associates with poor prognosis in human hepatocellular carcinoma.
Kong LM; Liao CG; Chen L; Yang HS; Zhang SH; Zhang Z; Bian HJ; Xing JL; Chen ZN
J Cell Mol Med; 2011 Jun; 15(6):1415-28. PubMed ID: 20629990
[TBL] [Abstract][Full Text] [Related]
11. Hypermethylation of ACP1, BMP4, and TSPYL5 in Hepatocellular Carcinoma and Their Potential Clinical Significance.
Qiu X; Hu B; Huang Y; Deng Y; Wang X; Zheng F
Dig Dis Sci; 2016 Jan; 61(1):149-57. PubMed ID: 26386860
[TBL] [Abstract][Full Text] [Related]
12. Downregulation of DENND2D by promoter hypermethylation is associated with early recurrence of hepatocellular carcinoma.
Kanda M; Nomoto S; Oya H; Takami H; Hibino S; Hishida M; Suenaga M; Yamada S; Inokawa Y; Nishikawa Y; Asai M; Fujii T; Sugimoto H; Kodera Y
Int J Oncol; 2014 Jan; 44(1):44-52. PubMed ID: 24189587
[TBL] [Abstract][Full Text] [Related]
13. Methylation of Tip30 promoter is associated with poor prognosis in human hepatocellular carcinoma.
Lu B; Ma Y; Wu G; Tong X; Guo H; Liang A; Cong W; Liu C; Wang H; Wu M; Zhao J; Guo Y
Clin Cancer Res; 2008 Nov; 14(22):7405-12. PubMed ID: 19010857
[TBL] [Abstract][Full Text] [Related]
14. Promoter hypermethylation of TERT is associated with hepatocellular carcinoma in the Han Chinese population.
Zhang H; Weng X; Ye J; He L; Zhou D; Liu Y
Clin Res Hepatol Gastroenterol; 2015 Oct; 39(5):600-9. PubMed ID: 25683523
[TBL] [Abstract][Full Text] [Related]
15. The aberrant expression of MEG3 regulated by UHRF1 predicts the prognosis of hepatocellular carcinoma.
Zhuo H; Tang J; Lin Z; Jiang R; Zhang X; Ji J; Wang P; Sun B
Mol Carcinog; 2016 Feb; 55(2):209-19. PubMed ID: 25641194
[TBL] [Abstract][Full Text] [Related]
16. Methylation of PCDH19 predicts poor prognosis of hepatocellular carcinoma.
Zhang T; Guan G; Chen T; Jin J; Zhang L; Yao M; Qi X; Zou J; Chen J; Lu F; Chen X
Asia Pac J Clin Oncol; 2018 Oct; 14(5):e352-e358. PubMed ID: 29749051
[TBL] [Abstract][Full Text] [Related]
17. Screening and verification of microRNA promoter methylation sites in hepatocellular carcinoma.
Ni X; Lin Z; Dai S; Chen H; Chen J; Zheng C; Wu B; Ao J; Shi K; Sun H
J Cell Biochem; 2020 Jul; 121(7):3626-3641. PubMed ID: 32065423
[TBL] [Abstract][Full Text] [Related]
18. Hypermethylation of secreted frizzled related protein 2 gene promoter serves as a noninvasive biomarker for HBV-associated hepatocellular carcinoma.
Xiang L; Chen LM; Zhai YJ; Sun WJ; Yang JR; Fan YC; Wang K
Life Sci; 2021 Apr; 270():119061. PubMed ID: 33454364
[TBL] [Abstract][Full Text] [Related]
19. Epigenetic silencing of TMEM176A activates ERK signaling in human hepatocellular carcinoma.
Li H; Zhang M; Linghu E; Zhou F; Herman JG; Hu L; Guo M
Clin Epigenetics; 2018 Nov; 10(1):137. PubMed ID: 30400968
[TBL] [Abstract][Full Text] [Related]
20. Pharmacological unmasking microarray approach-based discovery of novel DNA methylation markers for hepatocellular carcinoma.
Jung N; Won JK; Kim BH; Suh KS; Jang JJ; Kang GH
J Korean Med Sci; 2012 Jun; 27(6):594-604. PubMed ID: 22690089
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
